Melanoma & Skin Cancer

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Encorafenib plus binimetinib and nivolumab improved PFS in BRAF V600–mutant melanoma with symptomatic brain metastases.

On June 2, 2025, a group of oncologists gathered for an in-person workshop at the 2025 Annual Meeting of the American Society of Clinical Oncology to discuss advances in cutaneous squamous cell carcinoma (cSCC) treatment. Moderated by Soo Park, MD, the session focused on adjuvant, high-risk neoadjuvant and metastatic treatment, including the use of immune checkpoint inhibitors (ICIs). Faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Ahmad Tarhini, MD, PhD, discusses key findings from the EA6194 trial and how these data support the continued investigation of vidutolimod in melanoma.

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.

Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.

Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.